Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28274257 | 0.98 | HRH3 (0.33) | HRH3IDO1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5815185 | 0.73 | HRH3 (0.43) | HRH3IDO1ALDH1A1 | |
| SCHEMBL18341916 | 0.71 | ALDH1A1 (0.36) | HRH3IDO1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25861866 | 0.69 | ALDH1A1 (0.44) | HRH3IDO1ALDH1A1FKBP5 | |
| SCHEMBL6502793 | 0.69 | IDO1 (0.38) | HRH3IDO1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL27751556 | 0.69 | IDO1 (0.37) | HRH3IDO1CYP11B1CYP11B2CSNK1A1 | |
| SCHEMBL4325442 | 0.69 | IDO1 (0.37) | HRH3IDO1CYP11B1CYP11B2CSNK1A1 | |
| Hydrochloric Acid SCHEMBL5047885 | 0.68 | IDO1 (0.36) | HRH3IDO1CYP11B1CYP11B2CSNK1A1 | |
| Toyocamycin Aglycone SCHEMBL7698540 | 0.67 | CSNK1A1 (0.41) | PDE4APDE4BPDE4CPDE4DCSNK1A1 | |
| SCHEMBL15456616 | 0.67 | CSNK1A1 (0.37) | PDE4APDE4BPDE4CPDE4DCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020235902-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | 주식회사 보로노이 (KR) | 2020-11-26 | — | — | WO | claimed |
| WO-2020185044-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2020-09-17 | — | — | WO | claimed |
| WO-2020149723-A1 | PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2020-07-23 | — | — | WO | claimed |
| CN-109311896-A | Pyrazolopyrimidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2019-02-05 | — | — | CN | claimed |
| WO-2025106014-A1 | COMPOUNDS AND METHODS FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2025-05-22 | — | — | WO | disclosed |
| WO-2022260336-A2 | NUCLEOSIDE DERIVATIVE HAVING MULTI-TARGET KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER COMPRISING SAME | 퓨쳐메디신 주식회사 | 2022-12-15 | — | — | WO | disclosed |
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-12-28 | — | — | US | disclosed |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-07-30 | — | — | US | disclosed |
| EP-3478687-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2019-05-08 | — | — | EP | disclosed |
| CN-109311896-A | Pyrazolopyrimidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2019-02-05 | — | — | CN | disclosed |
| WO-2018004306-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-01-04 | — | — | WO | disclosed |
| EP-3201198-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016050804-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
| US-6831069-B2 | Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis | RIBAPHARM INC. | 2004-12-14 | — | — | US | disclosed |
| EP-1363581-A2 | PYRROLO(2,3-D)PYRIMIDINE NUCLEOSIDE ANALOGS | Ribapharm, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1212326-A4 | PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS | ICN PHARMACEUTICALS (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002100354-A2 | PYRROLO[2,3-D]PYRIMIDINE NUCLEOSIDE ANALOGS | RIBAPHARM INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1212326-A1 | PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS | ICN Pharmaceuticals, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | CEQUENT PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2001027114-A1 | PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS | ICN PHARMACEUTICALS, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | LRRK2, WEE1, WEE2 | HRH3 3042/4885IDO1 2428/4885CYP19A1 3412/4885 |
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | TYMP, DPYD, TYMS | HRH3 3443/4885IDO1 686/4885CYP19A1 4854/4885 |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | LRRK2, WEE1, WEE2 | HRH3 3042/4885IDO1 2428/4885CYP19A1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.